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Objective: To assess resistin hormone among type 2 males diabetic patients (T2DP) in 
Gaza Governorate. 
 Subjects and methods: It is a case control study included 90 males subjects, 45 of 
them were T2DP and the rest of them were 45 healthy non diabetic controls that 
matched each other in ages, sex and residence. A questionnaire interview was used as a 
tool of study. Serum resistin, glucose, insulin, cholesterol, triglycerides, high density 
lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and 
homeostasis model assessment of insulin resistance (HOMA –IR) were determined. 
Data were analyzed using SPSS version 18.0. 
Results: The mean ages of controls and cases were 50.93±5.74 and 51.64±4.76 years, 
respectively. Diabetes mellitus was more prevalent among individuals with family 
history of diabetes. Most of studied patients had had diabetes since less than 5 years. 
The self-reported complications among diabetic patients were hypertension, numbness 
in toes, heart diseases and retinopathy. Smoking or Physical activity had no association 
with serum resistin level (P>0.05). The BMI hadn‘t also any possible correlation with 
serum resistin level. The mean level of serum resistin had not any significant difference 
between diabetic patients and controls (P>0.05). Moreover the mean serum glucose 
levels in cases were significantly higher than that in controls (180.78±76.3 mg/dl Vs 
90.89±12.88 mg/dl)  (P=0.000) with no any significant correlation between resistin with 
glucose. The mean serum insulin an insulin resistant levels in cases were significantly 
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higher than that in controls (P>0.05). The average levels of cholesterol, triglycerides, 
HDL-C and LDL-C had not significantly difference in cases compared to controls. The 
Pearson correlation test revealed negative significant correlation between resistin and 
triglyceride or cholesterol (P<0.05). 
Conclusion: The preliminary study revealed that Serum resistin hasn‘t any significant 
relation with type 2 diabetes mellitus or insulin resistant. 
Keywords: Resistin hormon, Insulin hormone, Insulin resistant, Diabetes mellitus type 2, 
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حمٛٛى يغخٕٖ ْشيٌٕ انشٚغٛغخٍٛ نذٖ يشضٗ انغكش٘ انُٕع انثاَٙ  فٙ يحافظت 
 غضة
 يغخخهض انذساعت
ْدذا  ُيُ  ستيىىي مشسيىل يسشَتُتيىُى سيذي سشسيً يستيوشٌ يسايى  يسايذكٍ سيى يسيز ىس  ييٍ  اال : تق
 سحذ ظة غضة.
ُية ححي) جسجعىعية سشسيُة انطشق ٔاالدٔاث (.  سجعىعية سيذح ة-: قذست مزه يسذسيسة علً ساهج
سشَضييذ سيييى  سشسيييً يستيييوشٌ يساييى  يسايييذكٍ سيييى يسيييز ىس  54يسعجعىعيية يسعشسيييُة تىويييىل سيييى 
يذحُُى حعيشر يستيوشٌ. تي   54ويسعجعىعة يسضيذح ة تىويىل سيى  ُيش يسع سى يى  سيى يحايحذي غ
يىت عليً كىيذ   سيى  يسى ذحق حُى يسعجعىعىُى  ٍ يسجاس و يسععيش ويحقذسية  يٍ غيضة. وقيذ تي  يسح
ُيية سوييس سييى  يسشَتُتييىُى و يسجلى ييىص خيي ت يسعقذحليية يس  ييُة وياييشيي يساحىاييذو يسيُى ُعُذ  خ
ويحكتىسُى و يسوىسُتىشوت و يسذمىل يسا ثُة و يسذمىل يسيشوتُاُة ريو يسواذ ة يسعشتاعة و يسيذمىل 
 يسيشوتُاُة ريو يسواذ ة يسعاخاضة و تقُُ  كعىرج يسىىيصل سعقذوسة يحكتىسُى.
سيياة وسىىسييظ يسععييش سلعجعىعيية    50.93±5.74جعىعيية يسعشسييُة سىىسييظ يسععييش سلع انُخددا ح :
ساة. سشر يستوشٌ ي اش يكى ذسي حُى يحشخذص يسزَى سه  تذسَخ عذ لٍ    51.64±4.76يسضذح ة 
يذحُى حيذسعشر سايز يقيس سيى  سياىيو. تشيوتيت كتيية  4سلعشر, و سعظ  سشسً يستوش  يذكىي س
ُيس يحايذح  و يسيشير يسقلي  و يسعضذعاذو يسزيتُة سعشر يستوشٌ حُى يستاذ  س غظ يسيذ  و  تاع
يسيذكٍ وستىىي  طيعى ت شيوُة يسعُى. أشذسو يساىذ   يسً أكه ح َىاذ ع قة حُى يسىذخُى أو يسا ذ
مشسىل يسشَتُتىُى. وس  تايت أَضذ ع قة حُى سؤشش  ىلة يسجت  و ستىىي مشسىل يسشَتُتىُى, و 
سشَتُتيىُى حييُى يسعجعىعية يسعشسيُة ويسعجعىعيية ح َىايذ يخيى ف  يٍ سىىسييظ ستيىىي مشسيىل ي
يسضذح ة, ويسذ ستيىىي يسجلى يىص ومشسيىل يسشَتُتيىُى وسقذوسية يحكتيىسُى   قيذ  يذل سشتاعيذ  يٍ 
ىص أو ى يييسشسييً يستييوشٌ  عاييه  يييٍ يسعجعىعيية يسضييذح ة, وسيي  تاييييت يسذسيسيية ع قيية حييُى يسجل
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ى, و س  َخىلف ستىىي يسوىسُتىشوت يحكتىسُى يو سقذوسة يحكتىسُى س  ستىىي مشسىل يسشَتُتىُ
ُييية ريو يسواذ ييية  ُييية ريو يسواذ ييية يسعشتاعييية ويسيييذمىل يسيشوتُا ُييية ويسيييذمىل يسيشوتُا ويسيييذمىل يسا ث
يسعاخاضيية  يييٍ سشسيييً يستيييوشٌ عايييه  يييٍ يسعجعىعيية يسضيييذح ة, حُاعيييذ  يييذل مايييذ  ع قييية حيييُى 
 يسوىسُتىشوت ويسذمىل يسا ثُة س  ستىىي مشسىل يسشَتُتىُى.
يظهشو مزه يسذسيسة يألوسُة يكه ح ع قة حُى مشسىل يسشَتُتىُى وسشر يستوشٌ سى  خاج :االعخُ
 يساى  يساذكٍ يو سقذوسة يحكتىسُى .
سشسًي يستيوشٌ يسايى  يسايذكٍ مشسىل يحكتىسُى, سقذوسة يحكتيىسُى, , مشسىل يسشَتُتىُىانكهًــاث انًفخــاحٛــت : 
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1.1 Overview  
 Diabetes mellitus is the most common endocrine disorder in human, currently affecting 
over 170 million people world-wide and, potentially, over 365 million in the year 2030 
(Saini, 2010). Diabetes mellitus describes a metabolic disorder of multiple etiology 
characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and 
protein metabolism resulting from defects in insulin secretion, insulin action, or both 
(WHO, 1999). There are several distinct types of diabetes exist, but two most common 
types are type I diabetes and type 2 diabetes (Kota et al., 2012). 
Type 2 diabetes accounts for 75% of all diabetes cases (Ehtesham, 2001). It is one of 
the most prevalent chronic diseases in the world, which is characterized by insulin 
resistance coupled with a failure of pancreatic cells to compensate by adequate insulin 
secretion (Zhanga et al., 2010). 
The risk factors for T2DM include environmental influences such as obesity (especially 
abdominal obesity), aging, ethnicity, family history of diabetes, history of gestational 
diabetes, sedentary lifestyle, low birth weight, and polycystic ovary syndrome (Moneva  
& Dagogo-Jack.,  2002). Eighty percent or more of the people with T2DM are obese 
with the remaining twenty percent considered above ideal weight indicating obesity as a 
predominant link to the development of T2DM (Kahn & Flier., 2000).  
Insulin is a small globular protein containing two chains, A (21 residues) and B (30 
residues) (Weiss et al., 2009). It is synthesized exclusively in pancreatic islet B-cells by 
various stimuli, and gene mapping studies assigned the human insulin gene to 
chromosome 11 (Watanabe, 2011). Insulin is a pleiotropic hormone that exerts a 
multitude of effects on metabolism and various cellular processes in different tissues 
and organs of the body. The main metabolic actions of insulin are to stimulate glucose 
uptake in skeletal muscle and the heart and to suppress the production of glucose and 
very-low density lipoprotein (VLDL) in the liver (Jellinger et al., 2007). Other 
metabolic effects include inhibition of glucose release from the liver, inhibition of the 
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release of free fatty acids (FFAs) from adipose tissue, and stimulation of the process by 
which amino acids are incorporated into protein (Eckel et al., 2005).  
The first clinical evidence relating IR hyperandrogenism dates back to 1921 when 
Achard and Thiers described the existence of women with glucose intolerance and 
hirsutism (―the bearded diabetic woman”) (Espinós & Alsina., 2005). Insulin resistance 
is a characteristic of human obesity, and a primary risk factor for the (T2DM). 
However, despite tremendous effort and great progress in a number of areas of research, 
the biochemical mechanisms underlying the pathogenesis of insulin resistance in 
obesity remain poorly understood (Bhatt et al., 2006). 
Obesity is a worldwide health problem directly linked to several disease processes such 
as hypertension and type 2 diabetes mellitus (Liu et al., 2008). Obesity is generally 
defined as excessive body fat that results in increased risk for morbidity and mortality 
(Seo et al., 2012). Obesity occurs when energy intake exceeds energy expenditure. Our 
evolutionary history led to selection for consumption of high fat, protein rich and 
calorie dense food in times of plenty to protect against famine. The relatively recent 
availability of highly palatable, and energy dense food, combined with more sedentary 
lifestyles, have contributed to the global obesity epidemic (Chen & Morris., 2007). 
However, obesity is considered the most important risk factor for type 2 diabetes, as 
obese individuals are seven times more likely to develop than are normal-weight 
individuals. In addition, central obesity is strongly correlated with insulin resistance in 
type 2 diabetic patients (Gharibeh et al., 2010). 
Adipose tissue is an active secretory organ, sending out and responding to signals that 
modulate appetite, insulin sensitivity, energy expenditure, inflammation and immunity. 
Adipocytokines are proteins produced mainly by adipose tissue. These molecules have 
been shown to be involved in the pathogenesis of the metabolic syndrome and 
cardiovascular disease, For example, adiponectin, leptin, TNF alpha, interleukin and 
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Resistin is a novel 12.5 kDa cysteine-rich polypeptide secreted from adipocytes in 
rodents and humans. Resistin antagonizes insulin-stimulated glucose metabolism in 
muscle myocytes, hepatocytes, and adipocytes themselves (Zhong et al., 2002). 
However, the role of resistin in response to obesity and insulin resistance in type 2 
diabetic patients is still obscure. Several studies have reported increased resistin levels 
in association with obesity and insulin resistance in T2DM, whereas other studies have 
failed to detect any change in resistin levels under such conditions (Gharibeh et al., 
2010). Yet other studies found that circulating resistin levels are involved in promoting 
adiposity, but had no effect on the degree of insulin resistance (Laudes et al., 2010).  
 
1.2 General objective 
 To assess resistin hormone among type 2 male diabetic patients in Gaza strip.  
 
1.3 Specific objectives  
 To study resistin hormone among study population.  
 To measure insuline hormone, blood glucose and lipid profile among study 
population.    
 To verify possible relations between resistin hormone and anthropometric 
measures. 
 
1.4 Significance  
The prevalence rate of DM in Palestine is about 9% in 2000 (MOH, 2004). A new 
hormone which has not been studied before in Gaza strip is resistin. However, a lot of 
studies were carried out about resistin relation with obesity and insulin resistance in 
type 2 diabetes mellitus in many countries (Steppan et al., 2001 & Kusminski et al., 
2005), their results were controversial and most of them recommended to make further 











2.1 Diabetes mellitus  
Diabetes is a lack of insulin or presence of factors opposing the action of insulin, 
resulting in an increase (hyperglycemia) in blood glucose levels (Ehtesham, 2001). 
Diabetes mellitus may present with characteristic symptoms such as thirst, polyuria, 
Blurring of vision, and weight loss. In its most severe forms, ketoacidosis or a non-
ketone hyperosmolar state may develop and lead to stupor, coma and, in absence of 
effective treatment, death. Often symptoms are not severe, or may be absent, and 
consequently hyperglycemia sufficient to cause pathological and functional changes 
may be present for a long time before the diagnosis is made (WHO, 1999). T2DM is a 
multistage process that begins as insulin resistance, characterized by inability of the 
body to use its own insulin properly, and ends with exhaustion of the insulin producing 
pancreatic cells, thereby leading to hyperglycemia (Gharibeh et al., 2010). 
 
2.2 Pathophysiology of type 2 diabetes Mellitus 
2.2.1 Insulin hormone 
Insulin is a hormone required to facilitate transport of blood glucose across the largely 
impermeable cell membrane. It is released in response to elevations in blood glucose. 
The insulin binds to a receptor on the cell membrane, allowing the entry of glucose into 
muscle and fat cells to form glycogen, fatty acids to generate triglycerides, and amino 
acids for protein synthesis. It is thus an anabolic hormone. It is a potent stimulator of 
growth factors, including insulin growth factor 1 (IGF-1). It also inhibits catabolic 
processes such as the breakdown of glycogen and fat, and decreases gluconeogenesis 
(Cosford, 1999). 
 
2.2.2 Insulin sensitivity 
Insulin sensitivity refers to the ability of insulin to support glucose homeostasis by 
signaling insulin-sensitive tissues or organs to absorb glucose. These signals include 
stimulating glucose utilization in both muscle and adipose tissue and suppressing the 
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production of glucose by the liver. Both responses act to decrease plasma glucose 
concentration. The degree of impairment of glucose metabolism is influenced both by 
the insulin sensitivity of cells within the body and by pancreatic cell reserve capacity 
(Jellinger et al., 2007). 
 
2.2.3 Insulin resistance (IR) 
IR is a critical feature of T2DM that may be detected 10–20 years before the clinical 
onset of hyperglycemia (Zhao & Townsend., 2009). IR is present in the non-diabetic 
offspring of patients with type 2 diabetes; prospective studies demonstrating the 
usefulness of IR as a predictive marker of the future development of T2DM and 
prevention of diabetes by insulin sensitizing agents (Savage et al., 2005). 
 
Insulin resistance is defined as a failure of target tissues (adipose, liver, skeletal and 
cardiac muscle) to respond normally to insulin. At the molecular level, this resistance 
can occur anywhere in the insulin signaling pathway, from receptor binding to 
downstream signaling events (Steppan & Lazar., 2002). Under this condition, the islet 
β-cells in the pancreas secrete higher levels of insulin to compensate for the declined 
receptor function making hyperinsulinaemia a common characteristic in T2DM patients 
(Zhao & Townsend,. 2009 ). Although standard definitions of IR still define it in terms 
of the effects of insulin on glucose metabolism, the last decade has seen a shift from the 
traditional ―glucocentric‖ view of diabetes to an increasingly acknowledged 
―lipocentric‖ viewpoint. This hypothesis holds that abnormalities in fatty acid 
metabolism may result in inappropriate accumulation of lipids in muscle, liver, and β-
cells (savage et al., 2005). 
 
2.2.4 Insulin resistance mechanism 
Under hyperglycemic and hyperinsulinemic conditions, muscle glycogen synthesis is 
the major pathway for glucose metabolism in both normal and diabetic individuals, and 
that defective muscle glycogen synthesis plays a major role in causing insulin resistance 
in patients with T2DM (Shulman, 2000). Using multinuclear MRS approach, it was able 
to determine that glucose transport was the rate controlling step for insulin-stimulated 
muscle glycogen synthesis in T2DM, rather than hexokinase. Therefore, glucose 
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transport represents the best target to correct insulin resistance in skeletal muscle in 
patients of T2DM (Morino et al., 2006).  
 
Glucose-6-phosphate is an intermediate between glucose transport into the cell and its 
subsequent glycogen synthesis. The increment in glucose-6-phosphate concentration 
was significantly reduced in T2DM, suggesting that glucose transport or 
phosphorylation must be the rate-controlling step in insulin-stimulated glucose disposal 







Figure 2.1 Potential rate-controlling steps in insulin-stimulated glycogen synthesis 
in a myocyte. (Savage et al., 2005). 
 
2.2.5 Fatty acid–induced insulin resistance  
Increased plasma free fatty acid concentrations are typically associated with many 
insulin-resistant states, including obesity and T2DM (Shulman et al., 2000). Free fatty 
acids (FFAs) released from adipose tissue increase production of glucose and 
triglycerides (TGs) and secretion of very-low-density lipoprotein (VLDL) in the liver. 
Associated lipid/lipoprotein abnormalities include decreased levels of high-density 
lipoprotein cholesterol (HDL-C) and increased levels of small dense low-density 
lipoprotein (LDL) particles. FFAs also reduce insulin sensitivity in muscle by inhibiting 
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insulin mediated glucose uptake. Increases in circulating glucose increase pancreatic 
insulin secretion, resulting in hyperinsulinemia. Hyperinsulinemia may result in 
enhanced sodium reabsorption from kidney and increased sympathetic nervous system 
activity. It also may contribute to the development of hypertension see figure (2.2) 




Figure 2.2 Pathophysiology of insulin resistance (Jellinger et al., 2007). 
 
 Savage et al., (2005) originally showed that fatty acids compete with glucose for 
substrate oxidation in isolated rat heart muscle and rat diaphragm muscle. The 
mechanism they proposed to explain the insulin resistance was that an increase in fatty 
acids caused an increase in the intra-mitochondrial acetyl CoA/CoA and NADH/NAD+ 
ratios, with sub- sequent inactivation of pyruvate dehydrogenase (Figure 2.3). This in 
turn would cause intracellular citrate concentrations to increase, leading to inhibition of 
phosphofructokinase, a key rate-controlling enzyme in glycolysis. Subsequent 
accumulation of glucose-6- phosphate would inhibit hexokinase II activity, resulting in 
an increase in intracellular glucose concentrations and decreased glucose uptake. 





























Figure 2.3 Mechanism of fatty acid–induced insulin resistance in skeletal muscles 
(Shulman., et al 2000). 
 
Lipid accumulation within skeletal muscle and liver inhibits tyrosine phosphorylation of 
IRS-1. In turn, this follows serine phosphorylation of critical sites on IRS-1 and inhibits 
binding and activation of PI 3-kinase. A number of different serine kinases could be 
responsible for serine phosphorylation of IRS-1. Candidates include members of the 
novel protein kinase C family, which may be activated by accumulation of lipid 
intermediates, as well as inflammatory intermediates. The latter may be activated within 
adipose tissue in obese states. Lipid accumulation in skeletal muscle and liver may be a 
result of increased delivery/synthesis of fatty acids to/in these tissues in states in which 
energy intake exceeds adipose tissue storage capacity (as seen in obesity and 
lipodystrophy) or a consequence of either acquired or inherited mitochondrial 
dysfunction. (savage et al., 2005). 
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2.3 Obesity: 
Obesity is defined as abnormal or excessive fat accumulation that presents a risk to health. A 
crude population measured of obesity is the body mass index (BMI), with a BMI of 30 or more 
considered obese and BMI equal to or more than 25 considered overweight. Obesity has become 
a global epidemic, with more than 1 billion overweight adults and at least 300 million obese 
patient's worldwide (Chiang et al., 2011).  
 
BMI provides the most useful population-level measure of overweight and obesity as it 
is the same for both sexes and for all ages of adults but it is merely a rough guide 
because it may not correspond to the same degree of fatness in different individuals  
(Gupta et al., 2010 ). 
 
Adipose tissue plays a crucial role in the regulation of whole-body fatty acid 
homeostasis. In periods of calorie abundance it stores free fatty acids (FFAs) in the form 
of triglycerides through their esterification to glycerol and releases them back into the 
circulation in times of energy shortage (Galica., et al 2010). Obesity-induced insulin 
resistance is affected both by the total amount of adipose tissue and its distribution. 
Both visceral and deep subcutaneous adipose tissues are associated with insulin 
resistance. Excessive free fatty acids (FFAs) released by lipolysis from adipose tissue 
have been implicated in non-insulin dependent diabetes mellitus. FFAs compete with 
glucose for oxygen and inhibit whole body glucose disposal via the ‗Randle cycle‘. 
FFAs have a deleterious effect on insulin uptake by the liver and contribute to the 
increased hepatic glucose release (Steppan & Lazar., 2002). Adipose tissue is not only 
an organ for passive energy reserve, but also an active endocrine organ secreting a wide 
range of hormones and other protein factors called adipokines (Liu et al., 2008).  
 
2.4 Resistin  hormone  
Resistin, an adipocyte-derived hormone, which is associated with insulin resistance in 
vivo and in vitro, has been considered to link with T2DM. It serves as a signaling 
molecule between the energy storage organ, adipose tissue, and the principal insulin-
responsive organs: liver, muscle and fat and is considered to be a major contributor to 
insulin resistance in obesity (Steppan et al., 2001). 
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2.4.1 Discovery of resistin  
A new gene family named resistin-like molecules was discovered at almost the same 
time by different research groups. Initial studies showed that resistin was up-regulated 
in rodent models of obesity and insulin resistance and down-regulated by an insulin 
sensitizer RSG (rosiglitazone); however, Immunoneutralization of resistin reduced 
hyperglycemia and improved insulin sensitivity. (Kusminiski et al., 2005). 
 
2.4.2 The structure of resistin  
The human peptide consists of 114 amino acids including a 17 amino acids 61 signal 
peptides, a variable region of 37 amino acids, and a conserved C-terminus (Korner et al 
., 2005). The cysteine-rich peptide has molecular weight of 12.5 Kda and circulates in 
human plasma as a dimeric protein at levels ranging between 2.5 and 21.5 ng/ml (Silha 
et al., 2003). Variations in plasma resistin levels have been studied and its level appears 
to be fairly stable throughout the day. This is partly because of the fact that resistin does 
not seem to be regulated by eating and it has been seen that 48-h fasting did not affect 
plasma resistin levels. In addition, the level of resistin did not correlate with total energy 











Figur 2.4  Ribbon diagram representations of resistin. 
(A) Monomeric structure of resistin, whereas (B) shows its hexameric form comprising 
of two disulphide-linked trimers. (C) Highly exposed interchain disulphide  present in 
the hexameric form of resistin (Kusminisky et al., 2005) 
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2.4.3 Tissue distribution of resistin and other resistin-like molecule family 
members  
Resistin expression was first described in adipose tissue, with circulating levels detected 
in rodents and humans. Although the expression of resistin in mice was originally 
restricted to adipocytes, the principle origin of human resistin has remained somewhat 
contentious. Unlike the mouse gene, the human homologue of resistin was sparsely 
detectable in human adipocytes, this was confounded further by confusion over the 
proposed sites of resistin production. These studies led to many of the current 
perceptions that resistin was an inconsequential factor in the progression of obesity 
related T2DM, thereby contrasting rodent data (Kusminski et al., 2005). Conversely, 
McTernan et al, detected resistin in adipose tissue, thus describing resistin as a potential 
pathogenic factor increased in central adiposity (Mcternan et al., 2003). The 
discrepancy between studies may have partially related to methodology of detection or 
quantification of resistin. However, to date, although a difference in resistin mRNA 
levels between adipocytes and macrophages is apparent, studies have not yet identified 
whether this difference is observed at the protein level. Determining the relative 
contribution of the adipocyte in obesity with regards to circulating resistin levels would 
also prove beneficial (Kusminski et al., 2005). 
 
2.4.4 Regulation of resistin 
Resistin is tightly controlled by nutritional and hormonal conditions. Resistin is low in 
fasting conditions in parallel with glucose and insulin, and is restored upon re-feeding. 
Insulin appears to suppress resistin gene expression in 3T3-L1 adipocytes, 83 and 
hyperglycemia promotes resistin expression. Insulin-like growth factors, that are 84 
known to stimulate adipogenesis, down regulate resistin gene expression. The tissue 
level of resistin is decreased by insulin and cytokines such as TNFa, endothelin-1 and 
dexamethasone, and increased by growth and gonadal hormones and DHEA, 
hyperglycemia, male gender, and some pro inflammatory cytokines, such as IL-6 and 
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2.4.5 Regulation of resistin in models of insulin resistance and glucose 
intolerance 
In evaluating resistin and its association with insulin sensitivity in humans, several 
studies have identified positive correlations between resistin levels and insulin 
resistance in vivo and in vitro. Additionally, serum resistin levels were increased by 
approx. 20% in T2DM subjects, such findings have been re-affirmed by (Fujinami et 
al., 2004). In contrast, other studies have reported no associations between serum 
resistin levels and markers of insulin resistance in T2DM patients or insulin-resistant 
patients. Moreover, serum and plasma resistin levels were either reduced or increased in 
T2DM patients with no significant correlation with HOMA-IR (homoeostasis model 
assessment for insulin resistance), waist circumference, BMI or total cholesterol (youn 
et al., 2004) and (yang et al., 2003) Consequently, these studies suggest resistin is 
unlikely to play a critical endocrine role in insulin resistance or energy homoeostasis in 
humans. Nevertheless, a paracrine or autocrine manner of resistin to moderately affect 
metabolism cannot be ruled out (Kusminski et al., 2005). 
 
In the human context, early studies showed contradictory findings for correlations 
between resistin and glucose disposal, with recent studies still providing inconsistent 
results. Studies in Pima Indians have reported serum resistin effect of resistin on 
glucose homoeostasis levels were not associated with fasting glucose and insulin levels, 
although they were proportional to the degree of adiposity (Vozarova et al., 2004). 
Additionally, one study indicated serum resistin levels were inversely correlated with 
glucose disposal rates, whereas others indicate a modest effect of resistin on glucose 
uptake in vitro. Collectively, resistin transgenic and gene-deletion studies in rodents 
have provided evidence that resistin may have a predominant physiological role in the 
liver by contributing to the regulation of fasting blood glucose levels. Consequently this 
may have important implications in humans, but further studies regarding this are 
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2.4.6 Regulation of resistin by insulin sensitizers 
recent human studies have shed favorable light on the modulation of resistin by TZDs. 
Pioglitazone treatment suppressed plasma resistin concentrations in T2DM patients, 
which positively correlated with decreased hepatic fat content and improved insulin 
sensitivity. Furthermore, RSG reduced resistin secretion from human adipocytes and 
resistin expression in human macrophages. To understand whether the down regulation 
of resistin expression by RSG occurred through a direct PPAR-γ mediated 
transcriptional mechanism, identification of  five putative PPREs (PPAR-γ -response 
elements) in the resistin gene. One such response element, PPRE2, was shown to bind 
PPAR-γ. However, how PPAR-γ exerts its suppressive actions on resistin expression 
remains to be elucidated, although it has been suggested that recruitment of co-
repressors of transcription may play a role. RSG has also been shown to have anti-
inflammatory effects in human macrophages by reducing inflammatory cytokine 
production, which may consequently affect resistin production. Collectively, these 
human studies indicate that suppression of resistin expression may contribute to the 
insulin-sensitizing and glucose-lowering actions of the TZDs. Furthermore, the potential 
anti-inflammatory effects of TZDs on adipocytokine mediation may be of equal 
importance in the prevention of T2DM (Kusminski et al., 2005). 
 
2.4.7 Hormone and cytokine modulators of resistin expression 
Studies investigating metabolic hormones and cytokines that are associated with insulin 
resistance have looked for their relationship with resistin. Such studies have produced 
data suggesting an interplay between hormones, cytokines and resistin, as shown in 
Table (2.1). Although the reported regulation of resistin by these factors appears 
intriguing, no underlying mechanistic principles are currently apparent. Therefore the 
physiological relevance of most of these factors with respect to resistin remains to be 
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Table 2.1 Effects of hormones and cytokines on the level of resistin expression and 
secretion 
Effect on resistin Hormone/cytokine 
Growth hormone (somatotrophin; 1 mg ・ kg−1 ・ day−1) ↑ resistin 
gene expression (720–950 %) in WAT of spontaneous dwarf rats and 
has moderate inhibitory effects on resistin transcript and protein (30–
50 %) levels in 3T3-L1 adipocytes; ↑ gene expression levels in 
response to hyperprolactinaemia in mice;↓ mRNA and protein 






Dexamethasone ↑ mRNA and protein levels (2.5- to 3.5–fold) in 
3T3-L1 adipocytes and approx. 70 % in mouse WAT. 
 
Steroid hormones 
↑ In mice with elevated androgen levels; ↑ by hyperprolactinaemia 
and testosterone; administration of dehydroepiandrosterone ↑ gene 
expression in WAT of male Wistar rats; oestrogen ↓ adipose gene 
expression in ovariectomized rats and in isolated rat adipocytes in 




Severely ↓ expression in hyperthyroid rats; ↓ serum levels in subjects 
with hyperthyroidism. 
Thyroid hormone 
↓ Transcript and protein levels (30–50 %) in 3T3-L1 adipocytes. Adrenaline 
Intracerebroventricular administration of neuropeptide Y ↑ gene 
expression in mice WAT. 
 
Neuropeptide Y 
The β3-agonist isoproterenol ↓ gene expression levels in vitro by 20 





ET-1 (100 nM) ↓ basal secretion by 59 % in 3T3-L1 adipocytes. ET-1 
↓ Gene expression (approx. 50 %) in 3T3-L1 adipocytes; ↑ secretion 
from 3T3-L1 adipocytes; ↑ mRNA synthesis (23-fold) in 
streptozotocin-diabetic mice or Zucker diabetic fatty rats; gene 
expression and protein concentration ↑ in fasted mice; ↑resistin 





(Kusminski et al., 2005). 
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2.4.8 Resistin and obesity 
Recent investigations of human resistin in relation to obesity have shown higher serum 
resistin levels in obese subjects compared with lean subjects, which positively 
correlated with the changes in BMI and visceral fat area. The implication that resistin is 
important in human adipose tissue has been corroborated by studies showing increased 
protein expression with obesity, as well as protein secretion from isolated adipocytes. 
These recent observations are concomitant with initial studies that showed increased 
serum resistin levels and gene expression levels in abdominal depots in states of 
increased adiposity. A further study has shown a significant reduction in circulating 
resistin levels following moderate weight loss and post-gastric bypass. Collectively, 
these observations suggest resistin could indirectly be subjected to nutritional regulation 
in humans (Kusminski et al., 2005). 
 
Population based studies have not clarified the role of resistin in obesity. No correlation 
with BMI has been reported for example in a general population of 1090 subjects 
without medication recruited for a study of intima-media thickness (IMT) progression 
(Norata et al.,  2007) or in subjects with type 2 diabetes (n = 199) (Youn et al. 2004).  
In addition, in two large studies of 1922 and 1162 patients with or without CAD, 
resistin was not correlated with BMI (Lubos et al., 2007, Pilz et al., 2007). However, 
an association between resistin and obesity has been reported in almost as many papers 
as in those where no association was seen. The plasma resistin concentration has been 
associated with higher BMI in subjects with type 2 diabetes (n = 113) (Tokuyama et 
al., 2007), non-diabetic subjects (n = 123) (Aquilante et al., 2008), and asymptomatic 
subjects with family history of premature CAD (n = 879) (Reilly et al., 2005).  
 
A correlation between plasma resistin level and body fat mass or percent body fat has 
been reported in young 45 healthy subjects (Yannakoulia et al., 2003), patients positive 
for human immunodeficiency virus (HIV) (Barb et al.,  2005), as well as in overweight 
Pima Indians, where resistin was also associated with the increase in percent body fat 
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2.4.9 Resistin, insulin, insulin resistance and T2DM 
It is currently established that central obesity is a contributing factor to the pathogenesis 
of insulin resistance and consequently to T2DM. Although it is apparent that 
inconsistencies remain in the data for a role of resistin in obesity, there is a growing 
body of evidence suggesting a role for resistin in the etiology of insulin resistance and 
T2DM (Kusminski et al., 2005). Studies on the plasma resistin level in type 2 diabetes 
have described similarly conflicting results as the studies on obesity. There are studies 
that have reported higher plasma resistin concentrations in subjects with type 2 diabetes 
(Al-Daghri et al.,  2005, Al-Harithy & Al-Ghamdi 2005), whereas there is an almost 
equal number of studies in which no such difference has been observed (Fehmann & 
Heyn., 2002, Chen et al.,  2006). The association of resistin to diabetes is obscure since 
even those studies observing a difference in plasma resistin level between subjects with 
type 2 diabetes and controls have not always detected significant association between 
resistin and insulin resistance (Youn et al., 2004, Hasegawa et al., 2005, Koçak et al.,  
2007). Furthermore, the largest studies (n > 500) on plasma resistin concentration with 
the exception of the study of Pilz and co-workers (Pilz et al., 2007), have not detected 
any independent association with insulin resistance in different study populations 
(Reilly et al.,  2005 & Norata et al.,  2007). 
 
2.4.10 Functional roles of resistin and involvement in the disease 
 Steppan et al. (2001) made the original suggestion that resistin represented a hormone 
that links obesity to diabetes. The term resistin is derived from ―resistance to insulin‖ 
and the peptide was, indeed, demonstrated to counteract the beneficial effects of insulin 
by suppressing insulin signaling (Kusminski et al., 2005). Insulin resistance and 
dyslipidemia were found to be associated with resistin over expression  and resistin was 
shown to inhibit cellular glucose uptake, including by cardiomyocytes. Silha et al. 
(2003) demonstrated that plasma resistin correlated with insulin resistance in lean and 
obese human subjects. Other workers, however, reported that serum resistin was not a 
reliable predictor of insulin resistance when adjusted for BMI. Thiazoladinediones, used 
to treat insulin resistance in type 2 diabetes, and which are cardio protective drugs, have 
been shown to inhibit resistin synthesis by adipocytes and lower serum resistin 
(Steppan et al., 2001) 
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  Chapter 3 
Subjects and Methodology  
3.1 Study design 
It is a Case control study. 
 
3.2 Study population  
The target population was type 2 diabetic male aged 40-60 years from different diabetic 
clinic centers in Gaza Governorate.  
 
3.3 Sample size 
The sample size was 45 type 2 diabetic males and 45 healthy males served as controls. 
Patients and controls were also a matched each other in ages and residence. 
 
3.4 Sampling 
A total of 45 blood samples were collected from T2DP, which were previously 
diagnosed according to the current WHO diagnostic criteria for diabetes (WHO, 2006), 
from the diabetic clinic centers in Gaza Governorate. Blood samples were also collected 
from healthy persons who visited the clinic center with their relatives and were served 
as controls. 
3.5 Exclusion criteria 
1) Patients aged <40 and >60 years.  
2) Females. 
3) Blood diseased patients.  
4) Liver diseased patients. 
 
3.6 Data collection 
3.6.1 Questionnaire interview 
A meeting interview was used for filling in a questionnaire which designed for 
matching the study need for both cases and controls (Annex 1). All interviews were 
conducted face to face by the researcher himself and the help of the medical 
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technologists of al Remal clinic. During the survey the interviewers explained any of 
the questions that were not clear. The questionnaire was based on the questions of 
previous studies with some modifications (Jebril, 2012 & Shaat, 2012). Most questions 
were the yes/no questions which offer a dichotomous choice (Backestrom & Hursh-
Cesar, 1981). The questionnaire includes questions on the personal data (name, age, 
height, weight, family history of diabetes, smoking and sport) and clinical data 
including duration of DM and type of drugs (only for patients) and the most important 
complications of diabetes (retinopathy, numbness in toes, heart diseases, and 
hypertension). 
 
3.6.2 Body mass index 
Body mass index (BMI) was calculated as the ratio of body weight in Kg/height in 
Meter square. The subjects were asked to remove shoes and heavy clothes before 
measurement of weight and height. Participant with BMI=18.5–24.9 kg/m2 was 
Considered to have normal weight, Participants with BMI=25.0–29.9 kg/m2 was 
Classified overweight. Participants with BMI≥30.0 kg/m2 was considered obese 
(WHO, 2000). 
 
3.6.3 Specimen Collection 
Twelve hours fasting overnight venous blood samples were collected from the patients 
and non diabetic controls. Blood samples (5 ml each) were drawn by the researcher 
himself and the help of the medical technologists of al Remal clinic on Palestinian 
medical relief chronic disease clinic and by the team of al Remal clinic's medical 
technologists in vacationer and plastic tubes from the control and the diabetic patients. 
About 2 ml blood was placed into EDTA vacationer tube and the remainder quantity of 
blood (3 ml) was placed in plastic tube and left for a while without anticoagulant to 
allow blood to clot. Serum samples were obtained by centrifugation at 3000 rpm for 10 
minutes for the testing of : glucose, cholesterol, triglycerides, high density lipoprotein 
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3.7 Biochemical analysis 
3.7.1 Determination of serum resistin  
Serum resistin was determined by quantitative sandwich enzyme immunoassay 
technique by using R&D kit, USA. 
 
3.7.1.1 Principle of the assay 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for Resistin has been pre-coated onto a microplate. 
Standards and samples are pipetted into the wells and any Resistin present is bound by 
the immobilized antibody. After washing away any unbound substances, an enzyme-
linked monoclonal antibody specific for Resistin is added to the wells. Following a 
wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to 
the wells and color develops in proportion to the amount of Resistin bound in the initial 









Resistin Microplate - 96 Well Polystyrene Microplate (12 Strips Of 8 




Resistin Conjugate - 21 mL/vial of monoclonal antibody against 




Resistin Standard - 100 ng/vial of recombinant human Resistin in a 
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Wash Buffer Concentrate - 21 mL/vial of a 25-fold concentrated 
solution of buffered surfactant with preservatives. 
1 vial 
 








Stop Solution - 6 mL/vial of 2 N sulfuric acid. 
1 vial 
 
Plate Covers - Adhesive strips. 
4 strips 
 
3.7.1.3 Sample preparation  
Serum and plasma samples require a 5-fold dilution. A suggested 5-fold dilution is 60 
µL sample + 240 µL Calibrator Diluent RD5K. 
 
3.7.1.4 Reagents preparation  
Bring all reagents to room temperature before use. 
 Wash Buffer - If crystals have formed in the concentrate, warm to room temperature 
and mix gently until the crystals have completely dissolved. Dilute 20 mL of Wash 
Buffer Concentrate into deionized or distilled water to prepare 500 mL of Wash Buffer. 
 Substrate Solution - Color Reagents A and B should be mixed together in equal 
volumes within 15 minutes of use. Protect from light. 200 µL of the resultant mixture is 
required per well. 
 Resistin Standard - Reconstitute the Resistin Standard with 1.0 mL of deionized or 
distilled water. This reconstitution produces a stock solution of 100 ng/mL. Mix the 
standard to ensure complete reconstitution and allow the standard to sit for a minimum 
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of 15 minutes with gentle agitation prior to making dilutions. Pipette 900 µL of 
Calibrator Diluent RD5K into the 10 ng/mL tube. Pipette 500 µL into the remaining 
tubes. Use the stock solution to produce a dilution series (below). Mix each tube 
thoroughly before the next transfer. The 10 ng/mL standard serves as the high standard. 
Calibrator Diluent RD5K serves as the zero standard (0 ng/mL). Prepare fresh for each 





3.7.1.5 Assay procedure 
Bring all reagents and samples to room temperature before use. Samples, controls and 
standards were assayed in duplicate. 
1. Prepare all reagents, working standards, and samples as directed in the previoussections. 
2.   Remove excess microplate strips from the plate frame, return them to the foil pouch 
containing the desiccant pack, and reseal. 
3.   Add 100 µL of Assay Diluent RD1-19 to each well. 
4.   Add 100 µL of Standard, control, or sample per well. Cover with the adhesive strip 
provided. Incubate for 2 hours at room temperature. A plate layout is provided to record 
standards and samples assayed. 
5.  Aspirate each well and wash, repeating the process three times for a total of four 
washes. Wash by filling each well with Wash Buffer (400 µL) using a squirt bottle, 
manifold dispenser, or auto washer. Complete removal of liquid at each step is essential 
to good performance. After the last wash, remove any remaining Wash Buffer by 
aspirating or decanting. Invert the plate and blot it against clean paper towels. 
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6.   Add 200 µL of Resistin Conjugate to each well. Cover with a new adhesive strip. 
Incubate for 2 hours at room temperature. 
7.   Repeat the aspiration/wash as in step 5. 
8.   Add 200 µL of Substrate Solution to each well. Incubate for 30 minutes at room 
temperature. Protect from light. 
9.  Add 50 µL of Stop Solution to each well. The color in the wells should change from 
blue to yellow. If the color in the wells is green or the color change does not appear 
uniform, gently tap the plate to ensure thorough mixing. 
10. Determine the optical density of each well within 30 minutes, using a micro plate 
reader set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If 
wavelength correction is not available, subtract readings at 540 nm or 570 nm from the 
readings at 450 nm. This subtraction will correct for optical imperfections in the plate. 
Readings made directly at 450 nm without correction may be higher and less accurate. 
 
3.7.1.6 Quality control of resistin hormone kit 
Statistically significant number of controls was assayed to establish the mean values and 
acceptable range to assure proper performance and the validity of samples results 
according to control range. 
 
3.7.1.7 Calculation of the results 
1. Average the duplicate readings for each standard, control, and sample and subtract the 
average zero standard optical density. 
2. Plot the optical density for the standards versus the concentration of the standards and 
draw the best curve.  
3. The data can be linearized by using log/log paper and regression analysis may be 
applied to the log transformation. 
4. To determine the Resistin concentration of each sample, first find the absorbance value 
on the y-axis and extend a horizontal line to the standard curve. At the point of 
intersection, extend a vertical line to the x-axis and read the corresponding Resistin 
concentration. 
5. If the samples have been diluted, the concentration read from the standard curve must 
be multiplied by the dilution factor. 
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3.7.2 Determination of serum insulin  
insulin Serum was determined by quantitative sandwich enzyme immunoassay 
technique  by using DRG Kit ,Germany. 
 
3.7.2.1 Principle of the test  
The DRG Insulin ELISA Kit is a solid phase enzyme-linked immunosorbent assay 
(ELISA) based on the sandwich principle. The micro titer wells are coated with a 
monoclonal antibody directed towards a unique antigenic site on the Insulin  molecule.  
An aliquot of patient sample containing endogenous Insulin is incubated in the coated 
well with enzyme conjugate, which is an anti-Insulin antibody conjugated with Biotin. 
After incubation the unbound conjugate is washed off. During the second incubation 
step Streptavidin Peroxidase Enzyme Complex binds to the biotin-anti-Insulin antibody. 
The amount of bound HRP complex is proportional to the concentration of Insulin in 
the sample. Having added the substrate solution, the intensity of color developed is 
proportional to the concentration of Insulin in the patient sample. 
 
3.7.2.2 Reagents  
1. Microtiterwells, 12 x 8 (break apart) strips, 96 wells; Wells coated with anti-Insulin 
antibody (monoclonal). 
2. Zero Standard, 1 vial, 3 mL, ready to use 0 µIU/mL Contains non-mercury preservative. 
3.  Standard (Standard 1-5), 5 vials, 1 mL, ready to use; Concentrations: 6.25 - 12.5 – 25 - 
50 and 100 µIU/mL The standards are calibrated against international WHO approved 
Reference material NIBSC 66/304.; Contain non-mercury preservative. 
4. Enzyme Conjugate, 1 vial, 5 mL, ready to use, mouse monoclonal anti-Insulin 
conjugated to biotin; Contains non-mercury preservative. 
5. Enzyme Complex, 1 vial, 7 mL, ready to use, Streptavidin-HRP ComplexContains non-
mercury preservative. 
6.  Substrate Solution, 1 vial, 14 mL, ready to use, Tetramethylbenzidine (TMB). 
7. Stop Solution, 1 vial, 14 mL, ready to use, contains 0.5 M H2SO4, Avoid contact with 
the stop solution. It may cause skin irritations and burns. 
8. Wash Solution, 1 vial, 30 mL (40X concentrated), see "Preparation of Reagents". 
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3.7.2.3 Reagent Preparation 
 Bring all reagents and required number of strips to room temperature prior to use. 
 Wash Solution 
 Add deionized water to the 40X concentrated Wash Solution. 
 Dilute 30 mL of concentrated Wash Solution with 1170 mL deionized water to a final 
volume of 1200 mL.  
 The diluted Wash Solution is stable for 2 weeks at room temperature. 
 
3.7.2.4 Test Procedure 
Each run must include a standard curve. 
1. Secure the desired number of Microtiter wells in the frame holder. 
2. Dispense 25 µL of each Standard, control and samples with new disposable tips into 
appropriate wells.  
3. Dispense 25 µL Enzyme Conjugate into each well. Thoroughly mix for 10 seconds. It is 
important to have a complete mixing in this step. 
4. Incubate for 30 minutes at room temperature. 
5. Briskly shake out the contents of the wells. Rinse the wells 3 times with diluted Wash 
Solution (400 µL per well). Strike the wells sharply on absorbent paper to  remove 
residual droplets.  
Important note: The sensitivity and precision of this assay is markedly influenced by the 
correct performance of the washing  Procedure. 
6. Add 50 µL of Enzyme Complex to each well. 
7. Incubate for 30 minutes at room temperature. 
8. Briskly shake out the contents of the wells. Rinse the wells 3 times with diluted Wash 
Solution (400 µL per well). Strike the wells sharply on absorbent paper to remove 
residual droplets. 
9. Add 50 µL of Substrate Solution to each well. 
10. Incubate for 15 minutes at room temperature. 
11. Stop the enzymatic reaction by adding 50 µL of Stop Solution to each well. 
12. Determine the absorbance (OD) of each well at 450 ± 10 nm with a microliter plate 
reader. It is recommended that the wells be read within 10 minutes after adding the Stop 
Solution. 
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3.7.2.5 Calculation of the Results 
1. Calculate the average absorbance values for each set of standards, controls and 
patient samples. 
2. Using linear graph paper, construct a standard curve by plotting the mean absorbance 
obtained from each standard against its concentration with absorbance value on the 
vertical (Y) axis and concentration on the horizontal (X) axis. 
3. Using the mean absorbance value for each sample determine the corresponding 
concentration from the standard curve.  
4. Automated method: The results in the IFU have been calculated automatically using a 
4 PL (4 Parameter Logistics) curve fit. 4 Parameter Logistics is the preferred method. 
Other data reduction functions may give slightly different results.  
5. The concentration of the samples can be read directly from this standard curve. 
Samples with concentrations higher than that of the highest standard have to be further 
diluted or reported as > 100 µIU/mL. For the calculation of the concentrations this 
dilution factor has to be taken into account. 
 
3.7.3 Determination of serum glucose 
Serum glucose was determined by glucose oxidase (GOD)/glucose peroxidase (POD) 
method (Trinder,1969) using Daisys Kit, Germany 
 
3.7.3.1 Principle 
Determination of glucose after enzymatic oxidation by glucose oxidase. The 
colorimetric indicator is quinoneimine, which is generated from 4-aminoantipyrine and 
phenol by hydrogen peroxide under the catalytic action of peroxidase. 
Glucose + O2 → Gluconic acid + H2O2 






   
 44 
3.7.3.2 Reagents 












Glucose oxidase (GOD) 
 




≥ 1 ku/l 
 
Standard 100 mg/dl 
 
 
3.7.3.3 Assay procedure 
About 0.25 ml of serum was transferred to the Mindary Bs-200 Chemistry 
Auto analyzer, to perform the test according to these parameters: 
 
Reagent volume (µl) 250 
Serum volume (µl) 25 
Calibrator 1 (mg/dl) 2.7 
Incubation time (s) 60 
Wavelength (nm) 510 
Calibrator type Multi-points 
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3.7.3.4 Calculation 
Glucose [mg / dl] = ΔA sample X concentration of standard 
                                                
                                                   ΔA standard 
Reference value (fasting glucose) Adult: 75-115 mg/dl 
 
3.7.4 Determination of serum cholesterol 
Serum cholesterol was determined by cholesterol oxidase (COD)/POD method 
(Meiatlini et al., 1978) using Globe kit, Italy 
 
3.7.4.1 Method procedure  
The measurement is based on the following enzymatic reactions: 
                                                       
CHE 
Cholesterol esters + H2O         Cholesterol + Fatty acids 
                                         CHOD 
Cholesterol + O2         Cholest-4-en-3-one + H2O2 
                                                                                 POD 
2H2O2 + hydroxybenzoate + 4-Amminoantipyrine         Red complex+ 4H2O 
 
The intensity of the red complex is proportional to the total cholesterol present in the 
sample. 
3.7.4.2 Reagents 
Good buffer, pH 6.7 50 mmol/l 
Cholesterol oxidase (CHOD) ≥ 100 U/l 
Cholesterol esterase (CHE)                                   ≥ 300 U/l 
Hydroxybenzoic acid                                            12 mmol/l 
4-Amminoantipirine                                            0.3 mmol/l 
Peroxidase (POD)                     ≥ 500 U/l 
Sodio azide                                                          ≤ 0.095 g/l 
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3.7.4.3 Assay procedure 
About 0.25 ml of serum was transferred to the Mindary Bs-200 Chemistry 
Auto analyzer, to perform the test according to these parameters: 
 
Reagent volume (µl) 300 
Serum volume (µl) 250 
Calibrator 1 (mg/dl) 2.5 
Incubation time (s) 60 
Wavelength (nm) 510 
Calibrator type Multi-points 
Measurement Type End point 
 
3.7.5 Determination of serum triglycerides 
Serum triglyceride was determined by Glycerol phosphate oxidase/peroxidase method 
(Bucolo and David, 1973) using BioSystems kit, Spain. 
 
3.7.5.1 Principle 
Triglycerides in the sample onginates, by means of the coupled reactions described 
below colored complex that can be measured photometrically. 
 
Triglycerides + H2O    
LPL
      Glycerol + fatty acid 
 
Glycerol + ATP     
GK
          Glycerol-3-phosphate + ADP 
 
Glycerol-3-phosphate + O2    
GPO
          Dihydroxyaceton phosphate + H2 O2 
 
2H2O2 + Aminoantipyrine + 4-Chlorophenol    
POD
           Quinoneimine + HCI + 4H2O 
 
3.7.5.2 Reagents 
Good Buffer pH 7.2                           50 mmol/l 
ESPT                                                   4 mmol/l 
ATP                                                     2 mmol/l 
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Mg++                                                  2 mmol/l 
Lipoproteinlipase (LPL) ³                   1 kU/l 
Glycerol kinase (GK) ³                       0.4 kU/l 
Glycerolphosphate oxidase (GPO) ³  1.5 kU/l 
4-Amminoantipirine                          0.5 mmol/l 
Peroxidase (POD)                               >1 kU/l 
NaN3                                                 < 0.095 g/l 
 
3.7.5.3 Procedure 
About 0.25 ml of serum was transferred to the Mindary Bs-200 Chemistry 
Auto analyzer, to perform the test according to these parameters: 
 
Reagent volume (µl) 300 
Serum volume (µl) 250 
Calibrator 1 (mg/dl) 2.5 
Incubation time (s) 60 
Wavelength (nm) 510 
Calibrator type Multi-points 
Measurement Type End point  
 
3.7.5.4 Calculation 
Triglycerides [mg / dl] = ΔA sample X concentration of standard 
                                                              ΔA standard 
Reference value 
Adult (desirable) M   40 - 160 mg/dl 
 
3.7.6 Determination of serum High density lipoprotein cholesterol 
HDL-C was determined by precipitating method (Grove, 1979) using daisys kit, 
Germany 
3.7.6.1 Principle 
Chylomicrons, VLDL and LDL are precipitated by adding phosphotungstic acid and 
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magnesium ions to the sample. Centrifugation leaves only the HDL in the 




Monoreagent contain: Magnesium chloride      1.4 mmol/l 
Phosphotungstic acid                                        8.6 mmol/l 
Choesterol standard                                          200 mg/dl 
 
3.7.6.3 Assay procedure 
1. Precipitation 
 200 μl of standard (sample or control) was added to 500 μl of the precipitation 
reagent and mixed well. 
 The mixture was allowed to stand for 15 min at room temperature, and then 
centrifuged for 20 min at 4000 rpm.34 
 
2. Cholesterol determination 
Wavelength: 500 nm 
Optical path: 1cm 
Temperature: 37 ºC 
Measurement: against reagent blank. 
100 μl of the supernatant of standard (sample or control) was added to 1 ml of 
the cholesterol reagent and mixed well. 
The mixture was incubated for 5 min at 37 ºC. 
The absorbance was measured within 45 min. 
 
3.7.6.4Calculation  
HDL-C [mg/dl] =(A) Test x (C) Standard 
                            (A) Standard 
 
 Reference value = 35-65 mg/dl (PCLTG, 2005) 
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3.7.7 Determination of serum low density lipoproteins 
LDL-C can be calculated using the empirical relation of (Friedewald et al., 1972). 
 
3.7.7.1 Principle 
The ultra-centrifugation measurement of LDL-C is time consuming and expensive and 
requires special equipment. For this reason, LDL-C is most commonly estimated from 
quantitative measurements of total and HDL-C and triglycerides (TG) using the  
empirical relationship of Friedewald as follows: 
LDL-C = Total Cholesterol - HDL-C - TG/5. 
 
3.8 Data Analysis  
Statistical Package for Social Sciences (SPSS) software version 19 was used in 
summarizing, tabulation and analyzing the data. Several statistical procedures have been 
used for that purpose such as: Pearson correlation coefficient to find relationship 
between quantitative variables, frequency and descriptive analysis, parametric tests like 
independent samples T-test and analysis of variance. The independent samples T-test 
was used to examine if there is statistical significant difference between two means 
among the respondents. The One- Way Analysis of Variance (ANOVA) was used to 
examine if there is statistical significant difference between several means among the 

















4.1 Characteristics of the study population 
The sample size of the study population is presented in table 4.1 was consisted of   90 
subjects, 45 were type 2 male diabetic patients and 45 were controls. The controls 
matched the cases in sex, age and residence.   
 
Table 4.1. Sample size of the study population 
 
 Frequency Percent 
Controls 45 50% 
T2DM 45 50% 
Total 90 100% 
 
 
4.1.2 Age of the study population   
The age range of the study population was 40 to 60 years as shown in Table (4.2). The 
mean age for patients was 51.64 ± 5.74 years. The mean age for control group was 
50.93 ± 4.76 years. The independent sample t-test showed no significant difference 
between mean ages of controls and cases (P=0.524). 
 




Controls T2DM p- value by  T. 
test Mean Std. Deviation Mean Std. Deviation 
50.93 5.74 51.64 4.76 0.524 
P<0.05: significant 
 
4.1.3 Distribution of the study population with respect to DM duration 
Classification of cases according to duration of DM is presented in table 4.3. The first 
category is less than 5 years and it represented 60% of cases and the second category is 
for 5 years or more and it represented 40%. 
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≥ 5 year Count 18 
% 40% 




4.1.4 Distribution of the study population with respect to  Family history of 
T2DM 
Regarding to family history Table.4.4 indicates that 24 (53.3%) of controls and 34 of 
(75.6%) cases had family history of type 2 diabetes where as 21 (46.7%) and 11 
(24.4%) had not. The difference between the two groups was significance (P=0.023), 
indicating that family history is associated with type 2 diabetes. 
 




4.1.5 Self-reported complications of case group  
Figure 4.2 shows the main self-reported complications among diabetic patients. 
 The percentages of hypertension were 28.88%, numbness in toes were 31.11%, heart 
diseases were 17.77% and retinopathy in patient were 35.55%. 
 
Family history of 
T2MD 
Controls T2DM p- value by 
2   Frequency Percent % Frequency Percent % 
Yes 24 53.3 34 75.6 0.023 
No 21 46.7 11 24.4 
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Figure.4.2 Self- reported complications of the case group 
 
 
4.1.6 Smoking among study population 
 Table 4.5 shows that there was no statistically significance between controls and 
T2DM patients in smoking (P=0.50). In controls, 15.6% were smokers while 84.4% 
were nonsmokers. Among patients 17.8% were smokers and 82.2% were non-smokers.  
  




4.1.7 Physical activity of study population  
Table 4.6 reveals that There was a statistically significant difference between 
controls and T2DM patients with respect to physical activity (P=0.023). Among  
controls 75.6% of answers were yes for the question of  practicing sport while 
24.4% of answers were no for the same question. For T2DM patients, 53.3% of 




Controls T2DM p- value by 
2   Frequency Percent % Frequency Percent % 
Yes 7 15.6 8 17.8 0.50 
no 38 84.4 37 82.2 
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4.1.8 Type of treatment among case group 
 This figure 4.3 presents the types of treatments used by T2DM patients. The results 
showed that 2.20% were going on diet, 26.60% were using medical tablets, 11.10% 
were using both insulin and medical tablets, 37.70% were using tablets and making diet, 
6.60% were using insulin and diet, 4.40% were using insulin, diet and medical tablets & 
11.10% were without any treatment. 
 
 






Physical activity  
Controls T2DM p- value by 
2  Frequency Percent % Frequency Percent % 
Yes 34 75.6 24 53.3 0.023 
No 11 24.4 21 46.7 
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4.1.9 Body mass index (BMI) of the study population 
Table 4.7 shows that there was no significant difference in the mean BMI of T2DM 
patients compared to control (31.81±4.49 vs. 29.75±4.49kg/m2) (P=0.058). 
 
Table 4.7. Body mass index of the study population 
BMI 
(Kg/m2) 
Controls T2DM p- value by  T. 
test Mean Std. Deviation Mean Std. Deviation 
29.75 4.49 31.81 5.65 0.058 
BMI: Body mass index (Kg/m2): People with BMI=18.5-24.9 were considered to have 
normal weight, people with BMI=25.0-29.9 were classified overweight, people with 




4.2. Biochemical analysis 
4.2.1 Serum resistin level among the study population  
Table 4.8 shows the mean level of serum resistin among the study population. 
There was no statistically significant difference in the mean resistin of T2DM 
compared to controls (11.18±4.59 Vs 10.53±4.59 ng/mL)  ( P=0.506).  
 




4.2.2 Serum glucose level among the study population  
As indicated in Table 4.9 the mean serum glucose levels in T2DM patients were 






Controls T2DM p- value by  T. 
test 
Mean Std. Deviation Mean Std. Deviation 
10.53 4.59 11.18 4.59 0.506 
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Table 4.9. Serum glucose level among study population 
Glucose 
mg/dl  
Control T2DM p- value by  T. 
Mean Std. Deviation Mean Std. Deviation test 
90.89 12.88 180.78 76.03 0.000 
P<0.05: significant 
 
4.2.3 Serum insulin & HOMA-IR level among study population 
Serum insulin & insulin resistant (IR) level of the study population are presented in 
Table 4.10. There were significant increasing in serum insulin concentration and insulin 
resistant in cases (15.26±12.87 mg/dl and 6.34±5.75) compared to controls (9.30±5.02 
and 1.91 mg/dl ±.076). With (p=0.005 and p=0.000). 
 
Table 4.10. Serum insulin & HOMA-IR level among study population 
Parameters Controls T2DM p- value by  T.  
test 
 
Mean Std. Deviation Mean Std. Deviation 
Insulin 
Mg/dl 
9.30 5.02 15.26 12.87 0.005* 
HOMA-IR** 1.91 0.76 6.34 5.75 0.000* 
*P value of t-test: P<0.05: is significant 
**HOMA-IR: Homeostatasis Model Assessment for insulin resistance insulin resistant  
 
 
4.2.4 Lipid profile of the study population 
Table 4.11 presents serum lipid profile including cholesterol, triglycerides, HDL-C and 
LDL-C of the study population. There were no different significance in means of 
cholesterol, triglycerides, HDL-C and LDL-C in controls (204.71±39.47, 170.44±77.24, 
50.11±5.14 and 122.33±38.15 mg/dl, respectively) and in cases (203.18±52.82, 
180.82±85.28, 48.64±6.18 and 118.67±52.40 mg/dl, respectively) (P=0.876, P=0.547, 
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Table 4.11. Lipid profile of the Study population 
 
Parameters 
Control T2DM  


























170.44 77.24 180.82 85.28 0.547 
HDL-C* 
Mg/dl 
50.11 5.14 48.64 6.18 0.224 
LDL-C** 
mg/dl 
122.33 38.15 118.67 52.40 0.705 
*HDL—C : Height density lipoprotein cholesterol 
**LDL-C: low density lipoprotein cholesterol 
 P value of t-test: P<0.05:is significant 
 
 
4.2.5 Serum resistin compared with family history of the study population  
Table 4.12 shows that there was no association between serum resistin level and family 
history of T2DM in controls and in cases (P=0.641,P=0.191). 
 










 Group Statistics Independent Samples Test 
 N Mean Std. Deviation t df p- value 
yes 24 10.8333 5.55500 0.470 43 0.641 






 Group Statistics Independent Samples Test 
 N Mean Std. Deviation t df p- value 
yes 34 11.6882 4.58610 1.329 43 0.191 
no 11 9.5918 4.41484    
 
   
 49 
 
4.2.6 Serum resistin compared with physical activity  & smoking among 
study population 
As shown in table 4.13 physical activity or smoking had no significant association with 
the level of serum resistin among controls or among cases (P>0.05). 
 





Group Statistics Independent Samples Test 
 N Mean Std. Deviation t df p- value 
Physical 
activity 
yes 24 11.1983 4.26395 0.035 43 0.972 
no 21 11.1500 5.03639    
Smoking 
yes 8 10.6875 5.81278 0.329 43 0.744 
no 37 11.2814 4.36737    
 
 
4.2.7 Serum resistin correlated with age among study population 
Table 4.14 shows that by using Pearson correlation test there was no correlation 
between serum resistin and age in controls or in cases (P>0.05) 
 
Table 4.14. Serum resistin correlated with age among study population 
Resistin level Controls T2DM 
Age Pearson Correlation 0.182 0.101 
P-value 0.231 0.511 
: P<0.05: is significant 
Controls 
Resistin Group Statistics Independent Samples Test 
 N Mean Std. Deviation t df p- value 
Physical 
activity  
yes 34 9.8074 3.34164 -1.914- 43 0.062 
no 11 12.7636 6.95734    
Smoking yes 7 10.7571 5.61140    
no 38 10.4882 4.45949    
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4.2.8 Correlation of Serum resistin with BMI among study population 
Table4.15 shows that there was no correlation between serum resistin level and BMI in 
controls or in cases (P>0.05). 
 
 Table 4.15. Correlation of Serum resistin with BMI among study population 
Resestin level Controls T2DM 
BMI kg/m2* Pearson Correlation -.197- .012 
P-value .195 .940 
BMI: Body mass index 
P<0.05: is significant 
 
4.2.9 Correlation of resistin level with serum glucose level  
Table 4.16 shows that there was no correlation between serum resstin level and serum 
glucose in controls or in cases (P=0.590, P=0.750). 
 
Table 4.16. Correlation of resistin level with serum glucose level 
Resistin level Controls T2DM 
Glucose Pearson Correlation .084 .049 
P-value .590 .750 
P<0.05:is significant 
 
 4.2.10 Correlation of serum resistin with serum insulin & insulin resistance 
among the study population  
Table 4.17 shows that there was no correlation between serum resstin level and serum 
insulin or insulin resistant in controls or in cases (P>0.05). 
Table 4.17. Correlation of serum resistin with serum insulin and insulin 
Resistin level Controls T2DM 
Insulin Pearson Correlation .018 0.134 
P-value 0.908 0.378 
IR* Pearson Correlation 0.156 0.098 
P-value 0.307 0.523 
*IR:insulin resistant 
 
   
 21 
 
4.2.11 Correlation of serum resistin with lipid profile among the study 
population  
Table 4.18 shows that there was a negative significant correlation between serum 
resistin level and total cholesterol and triglyceride in controls. In the other hand there 
was no correlation between serum resistin level and   HDL-C or LDL-C in controls. In 
the case of T2DM patients serum resistin level has no correlation with cholesterol or 
triglyceride or HDL-C or LDL-C. 
 
Table 4.18. Correlation of serum resistin with lipid profile among the study 
population  




Pearson Correlation -0.328 0.267- 
P-value 0.028 .076 
Triglycerides Pearson Correlation -0.356 0.035 
P-value 0.016 0.822 
HDL-CL* 
 
Pearson Correlation 0.228 0.194 
P-value 0.132 0.202 
LDL-CL** Pearson Correlation 0.133 0.293 
P-value 0.383 .051 
*HDL—Cl : Height density lipoprotein cholesterol 
**LDL-Cl: low density lipoprotein cholesterol 

















5.1 Overview  
Diabetes mellitus is a common, serious metabolic disorder with diverse causes and 
multiple complications (McCowen & Smith., 2013). Diabetes affects more than 
177 million people worldwide, and its prevalence continues to grow. It is estimated by 
the World Health Organization that over 300 million people will be affected by diabetes 
by 2025, of which approximately 90% will be T2DM. As a continuous progressive 
metabolic disease, type 2 diabetes often begins with years of asymptomatic insulin 
resistance, which results in hyperglycemia and compensatory hyperinsulinemia (Chao 
& Liu., 2008). 
Adipose tissue is known to produce a vast array of adipocyte-derived factors, known as 
adipocytokines. Under ‗normal‘ physiological conditions adipocytokines may play an 
influential role in energy homoeostasis, triacylglycerol (triglyceride) storage and 
mobilization of fat, with increased adiposity, specifically central adiposity. These 
processes can be substantially dysregulated. Furthermore, it seems apparent that the 
pathogenesis of T2DM (Type II diabetes mellitus) is mediated through the concurrent 
progression of insulin resistance and subclinical inflammation, although the molecular 
mechanisms for this are less understood. It is, however, apparent that obesity represents 
one of the foremost contributory factors leading to diabetes, as such, the expression and 
functional properties of adipocytokines and their effects on metabolism have been the 
subject of intense research (Kusminski et al., 2005). 
Resistin, an adipocyte secreted hormone, has been suggested to link obesity with type 2 
diabetes and insulin resistance in rodent models, but its relevance to human diabetes 
remains uncertain(Mohammadzadeh et al., 2008). This study was carried out to assess 
resistin hormone level among T2DM patients and its relation and association with other 
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5.2 Characteristics of the study population 
This is a case control study included 90 males subjects, 45 of them were type 2 diabetic 
patients and the rest of them were 45 healthy non diabetic controls. 
 
5.2.1 Age and family history of the study population 
 The mean age of cases were 51.64±4.76 years and for controls were 50.93±5.74 years 
.It was reported that type 2 diabetes mellitus usually develops after the age 40 years 
(Rodger, 1991 and Umpierrez et al., 2006). The prevalence of diabetes was higher 
among individuals with family history of diabetes. These findings indicate that family 
history is associated with T2DM. This association not only highlights the importance of 
shared genes and environment in diabetes but also opens the possibility of formally 
adding family history to public health strategies aimed at detecting and preventing the 
disease. The presence of a family history of diabetes resulted to an early onset of the 
disease to the offspring ( Shaath., 2012). In the present study, in accordance with some 
previous ones (Vilarrasa et al., 2005) it did not reveal any changes in blood resistin 
concentrations with aging. This contradiction requires farther investigation with large 
sample size.    
 
5.2.2 Diabetes duration and Self-reported complications 
The present study data illustrated that 60% of patients had diabetics since less than 5 
years. This finding confirms the idea that type 2 diabetes has long asymptomatic pre-
clinical phase which frequently goes undetected. During this period of undiagnosed 
disease, risk factors for diabetic complications are developing (Canadian Diabetes 
Association Clinical Practice Guidelines Expert Committee, 2003). The most self 
reported symptoms among diabetic patients were hypertension, numbness in toes, heart 
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5.2.3 Smoking among study population 
This study indicated that there was no statically difference between cases and control in 
smoking. However several researchers suggested a significant association between 
smoking and diabetes, since smoking is considered as an enhancer for oxidative stress 
and a leading reason for hypertension. There is also substantial evidence that 
endothelium- dependent vasodilatation is impaired in smokers, type II diabetics, and in 
subjects with essential hypertension (Toledo et al., 2004). In contrast, the present study  
revealed that there was  no association between resistin level and smoking. That 
required further investigation with larger sample size. 
 
5.2.4 Physical activity among study population 
In this study there was a statically significant difference between controls and cases 
related to physical activity (P=0.023).This insures the role of physical activity in the 
prevention of diseases like T2DM. Although physical activity (PA) is a key element in 
preventing and management of T2DM, many with this chronic disease do not become 
or remain regularly active (American College of Sports  Medicine and the American 
Diabetes Association, 2010).  
Physical activity can influence the role of insulin in glucose entry into skeletal muscle  
by causing an insulin independent increase in the number of GLUT-4 transporters in 
muscle cell membrane. An increase in glucose entry persists for several hours after 
exercise and regular exercise training can produce prolonged increase in insulin 
sensitivity (Ganong 2005). This present study also revealed that there was no any 
association between resistin level and sport. 
 
5.2.5 Type of diabetic treatment among cases group 
The present study summarized the types of treatment used by T2DM patients. The most 
used treatment were tablets and diets together, then medical tablets alone. There were 
few patients not using these treatments because most of them hadn‘t discovered the 




   
 24 
 
5.2.6 Body mass index   
BMI is a measurement that compares individual's weight for height (kg/m2), and is 
usually used to assess obesity. Therefore, obesity is commonly defined as a BMI of 30 
Kg/m2 or higher. This definition distinguishes obesity from being pre-obese or 
overweight, which is classified as a BMI of 25 kg/m2 but less than 30 Kg/m2 (WHO, 
2000). In this study there was no significant difference between control and cases in 
BMI. It is expected; therefore that BMI should correlate with blood glucose levels.  This 
is, however, not always the case. A Scottish study has previously shown no significant 
correlation between random blood sugar levels and BMI (Janghorbani et al., 1991). 
Racial and other biological factors may be responsible for this difference as was 
suggested in a study involving Caucasian and African-American women (Dowling & 
Pi-Sunyer., 1993). As an indicator of adipocity BMI was tested for its correlation with 
resistin hormone level and because resistin is an adipocyte-secreted hormone, it appears 
reasonable to expect that it should be related to whole body or regional body adiposity. 
However, many human studies (Savage et al., 2001,  lee et al., 2003, McTernan et al., 
2003, Yang et al., 2003)  and this one have not found any evidence of this relationship. 
In contrast Some studies (Azuma et al., 2003, Degawa et al., 2003, Fujinami et al., 
2004) have reported a positive correlation between resistin level and BMI, and one 
particular group has demonstrated that the resistin level is associated positively with 
total body fat (Yannakoulia et al., 2003). 
Previous reports implied that adipocytes are not the only source of resistin hormone 
and, in fact, may not be the major source of resistin secretion in human beings. Such 
finding may explain why no relationship between resistin level and adiposity has been 
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5.3 Biochemical analysis  
5.3.1 Serum resistin level among study population 
The present finding shows that there was no significant difference in the level of serum 
resistin between controls and cases. There are also a number of studies indicated that 
there is  no significant difference between controls and T2DM patients  with respect to 
resistin level (Lee et al. 2003, Stejskal et al. 2003, Yaturu et al. 2006 & Norata et al. 
2007). However, there are an almost equal number of studies in which statically 
difference among the study population has been observed (McTernan et al. 2003, 
Zhang et al. 2003, Youn et al. 2004, Takata et al. 2008). A result that it seems 
depends on the size of sample used in each study. The study of Youn and colleagues 
was used more than 100 individuals in both groups (Youn et al. 2004). Schäffler et al., 
(2004) has reported that the plasma resistin level is lower in the group of type 2 
diabetics (n = 555) compared to healthy controls (n = 216).  
 
5.3.2 Serum glucose level among the study population 
As indicated in the present finding, the mean glucose levels in cases were significantly 
higher than that in controls. Similar results were obtained by Qi et al., (2007) and 
Yassin et al. (2011) who found that T2DP had higher fasting glucose levels than non-
diabetics. In diabetes, prolonged hyperglycemia super drives nonenzymatic protein 
glycation, which forms reversible Schiff bases and Amadori compounds. A series of 
further complex molecular rearrangements then yield irreversible advanced glycosylated 
end-products (AGEs). AGEs accumulate in the circulating blood and in various tissues 
(Furth, 1997). 
In this study no significant correlation between serum glucose and serum resistin was 
observed. Similarly studies in Pima Indians have reported serum resistin levels were not 
correlated with fasting glucose and insulin levels (Vozarova et al., 2004). Other studies 
indicated that resistin expression is reduced by fasting and hence low insulin level and 
increases rapidly on re-feeding and hence high insulin level (Steppan et al., 2001). 
 
5.3.3 Serum insulin and insulin resistant level among study population 
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The findings of this study revealed that serum insulin and IR mean level in T2DM was 
higher than those in controls. These results confirm the role of insulin hormone and IR 
in T2DM. Many people with IR have high levels of both glucose and insulin circulating 
in their blood at the same time. However, insulin resistance increases the chance of 
developing T2DM and heart disease (National Diabetes Information Clearinghouse. 
2008). 
In its correlation with resistin hormone this study didn‘t find any possible correlation 
between insulin hormone or IR. similarly other studies have reported no associations 
between serum resistin levels and markers of insulin resistance among T2DM patients 
(Lee et al., 2003 and Stejskal et al., 2003) or insulin-resistant patients (Hegele et al., 
2003). Moreover, serum and plasma resistin levels were either reduced or increased in 
T2DM patients with no significant correlation with HOMA-IR. In contrast, Silha et al., 
(2003) a reported a significant correlation between resistin and HOMA-IR. With regard 
to diabetes, a number of studies have described higher circulating resistin levels in 
diabetic as compared with non-diabetic subjects. This increase was not associated with 
markers of IR or adiposity(Zhang et al., 2003 and  McTernan et al., 2003) other 
studies in contrast reported that serum resistin concentrations were not significant 
different between diabetic and non-diabetic obese subjects. This contraelection in the 
finding about correlation of resistin with insulin or IR required further investigation  
 
5.3.4 Lipid profile of the study population 
Data presented in this study revealed no significant difference in the mean levels of 
cholesterol, triglycerides, HDL-C and LDL-C  in diabetic patients compared to controls. 
This study demonstrated that total cholesterol and triglycerides is negatively colerrated 
with resistin hormone in control group only. Another study has revealed that the serum 
resistin level is negatively associated with HDL-C level for both sexes. However, this 
relationship exists only when the data are analyzed by multiple linear regression and log 
resistin in female subjects. The biologic and physiological significance of this finding 
therefore needs to be proven. Jove et al (2003) reported the existence of a negative 
correlation between resistin mRNA level from white adipose tissue, total cholesterol, 
and LDL-C levels in 8 subjects subsequent to fenofibrate treatment. Those authors 
concluded that cholesterol regulated resistin expression within human white adipose 
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tissue. Other studies (Lee et al., 2003, Pfutzner et al., 2003 and McTernan et al., 
2003) however, similar to this finding current study, has not observed any relationship 
between resistin level and total cholesterol and LDL-C levels (Ching et al., 2005). In 
other studies, it has been demonstrated that resistin is associated with low HDL in 
healthy and T2DM (diabetes mellitus type 2) subjects (Eckel et al., 2005 and Ching et 
al., 2005). Mice, of which resistin is over-expressed in the liver by adenovirus, have the 
characteristics of Metabolic Syndrome  such as increased insulin resistance, low serum 
HDL and high triglyceride (Sato et al., 2005). Insulin is known to up-regulate 
lipoprotein lipase, a critical factor for the production of HDL, and the lipolysis of 





























Conclusions and Recommendations 
 
6.1 Conclusions 
 The mean ages of controls and cases were 50.93±5.74 and 51.64±4.76 years, 
respectively. 
 Diabetes mellitus is more prevalent among individuals with family history of diabetes. 
 Most of studied patients had diabetes since less than 5 years. 
 The self-reported complications among diabetic patients were hypertension, numbness 
in toes, heart diseases and retinopathy. 
 Smoking had no association with serum resistin level. 
 Physical activity had no association with serum resistin level.       
 The BMI hadn‘t any possible correlation with serum resistin levels.  
 The mean level of serum resistin had not any significant difference between diabetic 
patients and controls. 
 The mean serum glucose levels in cases were significantly higher than that in controls, 
and there was no any significant correlation with resistin. 
 The mean serum insulin an insulin resistant levels in cases were significantly higher 
than that in controls, with no any significant correlations with resistin. 
 The average level of cholesterol, triglycerides, HDL-C and LDL-C had not significantly 
difference in cases compared to controls. The Pearson correlation test revealed negative 
significant correlation between resistin and triglyceride or cholesterol.  
 
6.2 Recommendation  
 Further studies are recommended with large sample size to investigate the relation of 
resistin with IR and insulin level. 
 Researches on resistin hormone in a type of cell culture research are recommended.  
 Investigation of the association of hormone resistin with other diseases is also  
recommended. 
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 يستذدة يسوشي 
 يست   علُو  وستعة هللا ,,,,
أكذ يسيذت) سؤكس سشويل يسهاذٌ ج طذس  سذاتىُش تحذسُس طيُة حذسجذسعة يإلس سُة ( أساى يسعتذعذة  ٍ 
تيشعك ساذ حعُاة د  إلاشيي حعض يساحىاذو إتعذ  مزه يسذسيسة ورسك سى خ ت تعيئة مزي يحسىيُذل و
 يس يُة. 
 شاكشٍٚ نكى حغٍ حؼأَكى                                               
 
 :....................... سلى اندٕال                         ........................ :    اخخٛاس٘( )االعـــى
  : ......................انؼًـــــش
.......... ج     انــــٕصٌ: س  ,                             .........   انطـــٕل: 
...........: BMI... 
 
 يُز يخٗ حؼاَٙ يٍ يشع انغكش٘؟ .3
 ح أعذكٍ سى سشر يستوشٌ                 □
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  ساىيو ؟        تذد عذد يستاىيو .............  4أقس سى    □                  
 .........ساىيو ؟     تذد عذد يستاىيو...... 4أ اش سى                   □    
 ؟ انثاَٙ انُٕع يٍ انغكش٘ يشع يٍ ػا هخك أفشاد أحذ ٚؼاَٙ ْم .2
        □ح           □كع                        
 انمشابت ؟ دسخت ياْٙ : َؼى اإلخابت كاَج إرا............................. 
 ْم حؼاَٙ يٍ يشاكم طحٛت أٔ أيشاع ؟؟ .3
  إري  ذكت يإلاذحة كع  ير شمذ ؟         □ح           □كع                 
 تاعُس  ٍ أاذح  يسقذ    □يستاذ  سغظ يسذ                                □ 
     س ذ س  ٍ يسعُىل                                    □س ذ س  ٍ يسقل       □
 غُش رسك جتذد(...............   □ 
 
 دٔس٘؟ بشكم نذٚك انذو فٙ انغكش بفحض حمٕو ْم .4
  □ح         □كع                
 َؼى اإلخابت كاَج إرا: 
 ٗانغكش؟ بفحض لًج يشة أخش يخ............................................. 
 ؟......... بّ لًج فحض أخش فٙ انغكش يؼذل ْٕ يا.................................... 
 
 ؟ انحانٙ انٕلج فٙ حغخخذيّ انز٘ انؼالج َٕع ْٕ يا .5
 غزا ٛت حًٛت 




 ؟ حًايا بٓا يهخضو أَج فٓم انغزا ٛت انحًٛت حخبغ كُج إرا .6
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  □ح         □كع                       
 : انفى طشٚك ػٍ دٔاء ألشاص حغخخذو كُج إرا .7
 ؟ باَخظاو األلشاص ْزِ حخُأل فٓم            
  □ح         □كع              
 ؟ حغخخذيٓا انخٙ األلشاص اعى ْٕ يا ........................................... 
 
 ٔطفٓا انخٙ انًحذدة باندشػت انؼالج أخز ػهٗ يٕاظب أَج فٓم كؼالج األَغٕنٍٛ حغخخذو كُج إرا .8
 ؟ نٓا انًحذد انٕلج ٔفٙ انطبٛب نك            
  □ح         □كع                
 ؟ األخٛشة عُٕاث انخًظ خالل انًغخخذو األَغٕنٍٛ كًٛت فٙ حغٛٛش حذد ْم .9
  □ح         □كع               
 انخغبٛش؟ حدى ْٕ يا........................................ 
 
 ؟ األخٛشة عُٕاث انخًظ خالل انًغخخذو انؼالج َٕع فٙ حغٛٛش حذد ْم .01
  □ح         □كع               
 ؟ حذد انز٘ انخغٛٛش ْٕ يا : َؼى اإلخابت كاَج إرا............................................... 
 
 ؟ انشٚاضت إَٔاع يٍ َٕع أ٘ حًاسط ْم .00
  □ح         □كع                
 يذحٓا؟ كى ٔ حًاسعٓا انخٙ انشٚاضت َٕع ْٕ يا : َؼى إلخابتا كاَج إرا................................................. 
 
 ؟ انخذخٍٛ ػادة حًاسط ْم .02
  □ح         □كع               
 ص ؟ حذخٍ ٔأَج يخٗ يُز : َؼى اإلخابت كاَج إرا...................................... 
 
 ؟ انذو ضغط اسحفاعٍ ي حؼاَٙ ْم .03
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 □ح         □كع               
 َؼى اإلخابت كاَج إرا : 
 ؟ انذو ضغط اسحفاع يٍ حؼاَٙ ٔأَج يخٗ يُز .................................................... 
 انذو؟ ضغط اسحفاع نؼالج حغخخذيّ انز٘ انؼالج اعى ْٕ يا .................................................... 
 
 
ٙ حأخزْا؟ .35     ْم حظٍ أَك حؼش يؼهٕياث كافٛت ػٍ حانخك انظحٛت ٔ األدٔٚت انخ
 □ح           □كع                   
ٍ طبٛب نًؼاندت انغكش٘؟ .34   ْم حغخشٛش أكثش ي
 □ح             □كع                  
ٗ يشع انغكش٘؟ .06 ٍ انثمت فٙ انغٛطشة ػه  كى حًهك ي
 ويثق اذي          □               
 ويثق قلُ          □                
 سُس سذٌ أٌ ثقة   □               
 
 ْم حًهك خٓاص لٛاط َغبت انغكش فٙ انذو؟ .07
 □ح             □كع          
 كى يشة حمٛظ َغبت انغكش فٙ ديك باعخؼًال ْزا اندٓاص ؟ .08
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 حيحىٍ َىعلق يسزٌ يحسىيُذل مزي تعيئة علً سىي ق يكذ. 
 : ..........................................  يسىىقُ      
            يسىذسَخ:...........................................                                                
   تعذوكو  تتى علً سو  شوشي       
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